Zions Bancorporation National Association UT Raises Stock Position in Pfizer Inc. $PFE

Zions Bancorporation National Association UT increased its position in shares of Pfizer Inc. (NYSE:PFE) by 25.3% during the second quarter, HoldingsChannel.com reports. The fund owned 344,625 shares of the biopharmaceutical company’s stock after acquiring an additional 69,497 shares during the period. Zions Bancorporation National Association UT’s holdings in Pfizer were worth $8,354,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of PFE. Pacer Advisors Inc. increased its holdings in shares of Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after purchasing an additional 17,957,928 shares during the period. Amundi increased its stake in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after acquiring an additional 15,758,846 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Pfizer in the 1st quarter valued at about $389,861,000. Goldman Sachs Group Inc. boosted its position in shares of Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after acquiring an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Morgan Stanley lowered their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Bank of America upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $28.18.

Pfizer Stock Performance

Pfizer stock opened at $24.45 on Friday. The firm has a fifty day simple moving average of $24.74 and a two-hundred day simple moving average of $24.37. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a market capitalization of $138.99 billion, a PE ratio of 13.00, a P/E/G ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.